MAPT and Alzheimer disease: In this study, we test the ability of baseline in vivo measures of tau pathology, microglia activation, and brain atrophy to predict the rate of cognitive decline in patients with Alzheimer’s disease pathology, ranging from MCI (with biomarker evidence of amyloid pathology) to clinically probable Alzheimer’s disease (with dementia).